EmasenyieIsikweiMD

PubMed

• 18 citations
  A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412.
  Kara L Davis, Elizabeth Fox, Emasenyie Isikwei, Joel M Reid, Xiaowei Liu
  Clinical Cancer Research. 2022-12-01
• 16 citations
  FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer.
  Elizabeth S Duke, Amy K Barone, Somak Chatterjee, Pallavi S Mishra-Kalyani, Yuan-Li Shen
  Clinical Cancer Research. 2022-10-03
• 2 citations
  Feasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712.
  Katherine Tarlock, Xiaowei Liu, Charles G Minard, Emasenyie A Isikwei, Joel M Reid
  Pediatric Blood & Cancer. 2023-12-01

Journal Articles

• Risk Factors for Hypogammaglobulinemia in Chronic Lymphocytic Leukemia Patients Treated with Anti-Cd20 Monoclonal Antibody-Based Therapies  
  McNulty, Caitlin M., Emasenyie A. Isikwei, Pragya Shrestha, Melissa R. Snyder, Brian F. Kabat, Kari G. Rabe, Susan L. Slager, Sameer A. Parikh, and Avni Y. Joshi, Journal of Hematopathology, 10/1/2020

Abstracts/Posters

• Phase 1 study of pevonedistat (MLN4924) a NEDD8 activating enzyme inhibitor, in combination with temozolomide (TMZ) and irinotecan (IRN) in pediatric patients with rec...
  Jennifer Foster, Joel M. Reid, Charles G. Minard, Emasenyie Isikwei, Xiaowei Liu, Stacey L. Berg, Sarah Garrett Injac, Elizabeth Fox, Brenda Weigel, 2021 ASCO Annual Meeting, Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021) 10019-10019
• Feasibility of Pevonedistat Combined with Azacitidine, Fludarabine, Cytarabine in Pediatric Relapsed/Refractory AML: Results from COG ADVL1712
  Katherine Tarlock, Xiaowei Liu, Charles G. Minard, Sarah Menig, Joel M. Reid, Emasenyie Isikwei, Sharon Bergeron, Terzah M Horton, Elizabeth Fox, Brenda Weigel, Todd M..., 2021 ASCO Annual Meeting, Journal of Clinical Oncology, 5/28/2021
• Prediction of drug disposition using physiologically based pharmacokinetic (PBPK) modeling approach: Venlafaxine Extended Release formulation
  Emasenyie Isikwei, M.D., Julie Cunningham, Pharm.D., R.Ph, Carrie Krieger, Pharm.D., R.Ph, Joel Reid, Ph.D, ASCPT 2020, American Society for Clinical Pharmacology and Therapeutics, 9/2020
• Coverage of Pneumococcal Vaccine Among US Veterans 65years and Older: Estimates from Behavioral Risk Factor Surveillance System (BRFSS)
  Thelma C. Odoh, Chamberline E. Ozigbu, Efosa E. Aigbedo, Emasenyie Isikwei, et al., APHA 2019 Annual Meeting, 11/2/2019
• Hypogammaglobulinemia and Outcomes in Patients with Newly Diagnosed Chronic Lymphocytic Leukemia
  Isikwei E, Parikh SA, Kabat B, Reid JM, Joshi AY, ASCPT 2019, American Society for Clinical Pharmacology and Therapeutics, 10/2019
• Join now to see all